Who are Lopid's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Amvuttra, Egaten, Vyndaqel, Vyndaqel, Vyndaqel, Vyndaqel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/gemfibrozil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Lopid — Competitive Intelligence Brief

Lopid (GEMFIBROZIL) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Peroxisome Proliferator Receptor alpha Agonist [EPC]. Area: Metabolic.

marketed Peroxisome Proliferator Receptor alpha Agonist [EPC] Transthyretin Metabolic Small molecule Live · refreshed every 30 min

Target snapshot

Lopid (GEMFIBROZIL) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Lopid TARGET	GEMFIBROZIL	Pfizer	marketed	Peroxisome Proliferator Receptor alpha Agonist [EPC]	Transthyretin	1981-01-01
Amvuttra	VUTRISIRAN	Alnylam Pharmaceuticals	marketed	Small Interfering RNA	transthyretin (TTR) mRNA	2022-01-01
Egaten	TRICLABENDAZOLE	Novartis	marketed	Anthelmintic [EPC]	Transthyretin	2019-01-01
Vyndaqel	tafamidis-test	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01
Vyndaqel	Tafamidis Meglumine	Foldrx Pharms	marketed	Transthyretin stabilizer	Transthyretin (TTR)	2019-01-01
Vyndaqel	tafamidis	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01
Vyndaqel	Tafamidis	Foldrx Pharms	marketed	tafamidis	Transthyretin	2019-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2035-08-31 — Vyndaqel · 9770441 · US

Sponsor landscape (Peroxisome Proliferator Receptor alpha Agonist [EPC] class)

Pfizer · 1 drug in this class
Pfizer Inc. · 1 drug in this class
Salix · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lopid — Competitive Intelligence Brief. https://druglandscape.com/ci/gemfibrozil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab